DUBLIN–(BUSINESS WIRE)–The “Global
Erectile Dysfunction (ED) Drugs Market 2019-2023” report has
been added to ResearchAndMarkets.com’s offering.
The erectile dysfunction (ED) drugs market will register a CAGR of over
4% by 2023.
The high prevalence of conditions resulting in ED is one of the key
factors expected to trigger the market’s growth in the forthcoming
years. Various health conditions including diabetes, hypertension,
obesity, depression, stress, and excessive alcohol consumption are
resulting in the rising incidences of ED among elderly as well as young
people. As these conditions directly alter the normal physiological
levels of hormones, enzymes, and other factors, problems including
penile erection have surged considerably in the recent years. These
issues will further lead the erectile dysfunction drugs market to
register a significant growth in the forthcoming years.
Market Overview
Rising demand for ED drugs
One of the growth drivers of the global erectile dysfunction (ED) drugs
market is the rising demand for ED drugs. The rising cyber pornography
and the increasing number of advertisements for the treatment of ED are
expected to propel the growth of the global erectile dysfunction (ED)
drugs market during the forecast period.
Side effects of available drugs
One of the challenges in the growth of the global erectile dysfunction
(ED) drugs market is the side effects of available drugs. The
alterations in the blood flow, which are caused by ED drugs, result in
side-effects such as headache, vision changes, and dizziness, which will
hinder the growth of the market.
Competitive Landscape
The market appears to be moderately concentrated with the presence of a
few market players. Many vendors in the market are focusing on expanding
research for the development of novel therapies such as stem cells for
the treatment of ED. This market research report will help clients
identify new growth opportunities and design unique growth strategies by
providing a comprehensive analysis of the market’s competitive landscape
and offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Oral drugs – Market size and forecast 2018-2023
- Topical drugs – Market size and forecast 2018-2023
- Others – Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2018-2023
- Europe – Market size and forecast 2018-2023
- Asia – Market size and forecast 2018-2023
- ROW – Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bayer AG
- Eli Lilly and Company
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- VIVUS Inc.
PART 15: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/9k2g7g
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Sexual
and Reproductive Health Drugs